Department of Pediatric Otolaryngology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania 15224, USA.
Otolaryngol Head Neck Surg. 2011 May;144(5):789-93. doi: 10.1177/0194599810395082.
To review the 2-year, single-institution experience with injection laryngoplasty for diagnosis and treatment of type 1 laryngeal clefts (LC-1).
Case series with chart review.
Tertiary care academic children's hospital.
Patients at our institution who underwent injection laryngoplasty for LC-1 from January 2008 to December 2009. Outcome measures included patient demographics, surgical and anesthetic technique, effect on swallowing, and complications. Preoperative and postoperative swallowing evaluations were compared, and quality and duration of effects were calculated.
Sixteen children, 9 male and 7 female, underwent injection laryngoplasty for LC-1. Mean gestational age was 36.4 weeks (SD, 4.0 weeks; range, 27-41 weeks). Six patients had a major congenital anomaly (37.5%). Mean age at injection was 11.8 months (SD, 8.9 months; range, 2.9-33.5 months). Nine patients (56%) demonstrated complete resolution of penetration and aspiration on postoperative modified barium swallow (MBS), 4 patients (25%) had some improvement, and 3 patients (19%) showed no change. There were no complications. Mean duration of symptom improvement was 3.3 months (SD, 3.0 months; range, 0-11 months). Five patients went on to have definitive surgical LC-1 repair.
Injection laryngoplasty was found to have favorable results in this group of patients with LC-1. Most patients experienced complete resolution of aspiration on MBS, and no patients experienced complications. These findings support the further study of injection laryngoplasty for LC-1 as both a diagnostic and therapeutic technique. Longer followup intervals are necessary to elucidate the predictive value with regard to success of formal cleft repair.
回顾单中心 2 年注射性喉成形术治疗 1 型喉裂（LC-1）的经验。
病例系列，图表回顾。
三级保健学术儿童医院。
2008 年 1 月至 2009 年 12 月期间，我院对 LC-1 患者行注射性喉成形术。结果测量包括患者的人口统计学资料、手术和麻醉技术、吞咽效果以及并发症。比较术前和术后吞咽评估，并计算质量和效果持续时间。
16 例患儿，9 例男性，7 例女性，因 LC-1 行注射性喉成形术。平均胎龄为 36.4 周（标准差，4.0 周；范围，27-41 周）。6 例患儿存在重大先天性异常（37.5%）。注射时的平均年龄为 11.8 个月（标准差，8.9 个月；范围，2.9-33.5 个月）。9 例（56%）患儿术后改良钡剂吞咽检查（MBS）显示完全消除了穿透和吸入，4 例（25%）有一定改善，3 例（19%）无变化。无并发症。症状改善的平均持续时间为 3.3 个月（标准差，3.0 个月；范围，0-11 个月）。5 例患者进一步接受了确定性手术 LC-1 修复。
在这组 LC-1 患者中，注射性喉成形术的结果令人满意。大多数患者在 MBS 上完全消除了吸入，无患者发生并发症。这些发现支持进一步研究注射性喉成形术治疗 LC-1，将其作为一种诊断和治疗技术。需要更长的随访时间来阐明与正式裂隙修复成功相关的预测价值。
